Overview

A Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Status:
Recruiting

Trial end date:
2023-11-21

Target enrollment:

Participant gender:

Summary

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Loxo Oncology, Inc.

Collaborator:

Eli Lilly and Company